Chris Anzalone
Founder

Chris Anzalone’s background combines biomedical research, investment banking, financial services, and venture capital. He is founding CEO of the Benet portfolio company Nanotope, Inc., a tissue regeneration company built on platform technology developed by Dr. Samuel I. Stupp, Director of Northwestern University’s Institute for BioNanotechnology in medicine. Dr. Anzalone is also founding CEO of Benet portfolio company, Leonardo Biosystems, a cancer drug delivery company built with Dr. Mauro Ferrari, President of the Texas Alliance for NanoHealth.

Prior to Benet, Dr. Anzalone was a partner at the private equity firm Galway Partners, LLC in Washington DC. There, he was involved in sourcing, developing and structuring new business ventures. While at Galway, he was the founding CEO of NanoInk, Inc., a leading nanolithography company addressing biotechnology and semiconductor markets. Dr. Anzalone served as acting CEO and Chairman for two years and built NanoInk from a raw university-developed technology into a revenue-producing company with multiple partners and customers. Other Galway start-up companies included Columbia Partners, an asset management firm; Financial Passport, an online financial services company acquired by Ameritrade (Nasdaq: AMTD); and Applied Predictive Technologies, a leading provider of adaptive software solutions for retailers.

Prior to joining Galway, Dr. Anzalone was an NIH Fellow at the Smithsonian Institution’s Conservation and Research Center, specializing in altered germ cell DNA-protein interactions. He was an active scientist with publications in the areas of Molecular Biology, Endocrine Physiology, Reproductive Biology, and Conservation Biology. He holds an M.A. and Ph.D. in Biology from UCLA and a B.A. in Government from Lawrence University.